DrugRepV_1673 | Thiabendazole | Dermatologicals; Antiparasitic products, Insectisides and Repellents | Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
DrugRepV_1744 | Thiabendazole | Dermatologicals; Antiparasitic products, Insectisides and Repellents | Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
DrugRepV_1815 | Thiabendazole | Dermatologicals; Antiparasitic products, Insectisides and Repellents | Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
DrugRepV_2665 | Thiabendazole | Dermatologicals; Antiparasitic products, Insectisides and Repellents | Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3865744 %) | Approved | 27742486 |